Articles 566 | VOL.11 NO.5 | MAY 2014 | nAture methods the accurate and comprehensive identification of functional regulatory sequences in mammalian genomes remains a major challenge. here we describe site-specific integration fluorescence-activated cell sorting followed by sequencing (siF-seq), an unbiased, medium-throughput functional assay for the discovery of distant-acting enhancers. targeted singlecopy genomic integration into pluripotent cells, reporter assays and flow cytometry are coupled with high-throughput dnA sequencing to enable parallel screening of large numbers of dnA sequences. By functionally interrogating >500 kilobases (kb) of mouse and human sequence in mouse embryonic stem cells for enhancer activity we identified enhancers at pluripotency loci including NANOG. in in vitro-differentiated cardiomyocytes and neural progenitor cells, we identified cardiac enhancers and neuronal enhancers, respectively. siF-seq is a powerful and flexible method for de novo functional identification of mammalian enhancers in a potentially wide variety of cell types.
Currently, most putative enhancers are identified via chromatinbased assays, such as chromatin immunoprecipitation followed by sequencing (ChIP-seq) or DNase digestion followed by sequencing (DNase-seq) 3, 6, 8 . Such assays predict enhancer elements indirectly based on their association with specific transcription factors, transcriptional coactivators, chromatin structure or epigenomic marks. One limitation of these approaches is that they are associated with false positive and false negative errors, and putative enhancers predicted this way must be validated with functional reporter assays 14, 15 . Because of this limitation and the cell type-specificity of enhancers, there is a pressing need for higher-throughput functional enhancer assays that can be used in a wide variety of cell types and developmental contexts.
To enable unbiased, higher-throughput identification of mammalian enhancers in biologically relevant cell types, we developed SIF-seq. This method can be used for de novo discovery of mammalian enhancers across large genomic intervals and for medium-throughput validation of putative enhancers predicted by chromatin-based methods. Unlike previous medium-throughput and high-throughput enhancer assays for mammals [16] [17] [18] , SIF-seq includes the integration of putative enhancers into a single genomic locus 19 . Therefore, the activity of enhancers is assessed in a reproducible chromosomal context rather than on a transiently expressed plasmid. Furthermore, by making use of embryonic stem (ES) cells and in vitro differentiation, SIF-seq can be used to assess enhancer activity in a wide variety of disease-relevant cell types.
We used SIF-seq to randomly interrogate genomic intervals, at a resolution of ~1 kb, and identified ES cell enhancers near genes involved in pluripotency or early embryogenesis (mouse and human Nanog and NANOG, and mouse Sall1). We identified cardiomyocyte enhancers near genes that regulate heart development (human MYH6 and MYH7) and assessed the activity of putative enhancers in neural progenitor cells. results siF-seq accurately identifies mouse es cell enhancers For the de novo identification of mouse ES cell enhancers, we constructed two enhancer test libraries by shearing two bacterial artificial chromosomes (BACs) containing loci of interest into ~1-1.6 kb fragments ( Fig. 1, Table 1 and Supplementary Fig. 1 ). The first BAC (RP23-225H20) covered ~231 kb of mouse genomic sequence, including the Sall1 gene. In mouse ES cells, this region has a high density of sites that are marked with H3K27ac or the histone acetyltransferase p300 ( Supplementary Fig. 2) 3 , both strong predictors of enhancer activity 14, 15 . The second BAC (RP24-73P7) contained ~233 kb of mouse sequence encoding several genes, including the pluripotency gene Nanog (Supplementary Fig. 3a) . We cloned the sheared BAC fragments into a genomic targeting plasmid next to a gene encoding the Venus yellow fluorescent protein 20 that is under the control of a minimal promoter. We then delivered the resulting plasmids to Hprt-deficient male mouse ES cells, where these plasmids integrated by homologous recombination into the Hprt locus on the X chromosome 19 , and we used drug selection to remove any cells that were not correctly targeted. This resulted in ES cell libraries in which every cell had exactly one potential enhancer sequence coupled to a reporter gene integrated as a single copy in the Hprt locus, a site that has been previously shown to be a suitable neutral region to study the activity of tissue-specific regulatory elements 21 .
To identify the active ES cell enhancers present in the tested regions, we used fluorescence-activated cell sorting (FACS) to isolate cells with robust reporter expression ( Fig. 2a) . To calibrate the sorting process, we used populations transfected with two DNA fragments that had no or strong enhancer activity as negative and positive controls, respectively. Cells from the negative control showed universally low reporter expression, in contrast to the positive control, in which the majority of cells showed very strong Venus expression. Each ES cell library from randomly sheared BACs contained a small population of cells with robust reporter expression and a large population with negligible reporter expression, which is expected considering that any given genomic locus is likely to harbor only a few enhancers active in any given cell type. We collected by FACS the Venus-expressing cells, which are expected to contain an enhancer activating reporter gene expression, and amplified the enhancer sequences in these fluorescent cells by PCR using universal primers that recognize the sequences flanking the enhancer site.
We then sequenced enhancer amplicons using high-throughput sequencing technology and mapped the reads to the BAC reference sequence.
To determine which sequences we tested in each library and to control for biases in the library construction, we amplified and sequenced candidates present in an unsorted sample of each ES cell library, analogous to a ChIP-seq input sample. We defined functionally active enhancers as those sequences that showed a significant enrichment in the fluorescent cell population relative to the input control (Online Methods).
For both BACs, we constructed ES cell libraries containing a diverse collection of DNA fragments that in total randomly covered ~85% of each BAC region (Supplementary Table 1 , and Supplementary Figs. 2 and 3a) . Both libraries showed strong enrichment of a small number of putative enhancer sequences in the reporter-expressing cell types ( Fig. 2b, and Supplementary  Figs. 2 and 3a) . Testing of the same BAC region using different versions of the Hprt targeting plasmid supported the reproducibility of the assay (Supplementary Note). In the assayed regions, we re-identified a previously described ES cell enhancer ~5 kb upstream of Nanog 22 as well as a new putative enhancer between Nanog and Dppa3, more than 40 kb away from the Nanog transcription start site. We also identified a putative enhancer ~25 kb upstream of Slc2a3 and three putative enhancers downstream of Sall1. Recently published chromatin interaction data support the role of these sites as enhancers by demonstrating a physical interaction between the majority of these putative enhancers and at least one promoter, including those for the genes Nanog, Sall1, Slc2a3 and Gdf3 (Supplementary Fig. 4 ) 23 . These results suggest that SIF-seq can correctly identify ES cell enhancers present in complex libraries of DNA sequences.
To confirm the accuracy of our enhancer discovery, we examined the enhancer activities of the six candidate enhancer sites that were identified by SIF-seq and of 14 sites with no predicted npg enhancer activity (referred to as 'enhancer-negative'), including four loci that were enhancer-negative by SIF-seq but showed strong p300 and/or H3K27ac interaction in mouse ES cell ChIPseq experiments 3 and ten randomly chosen sites. We cloned each site, linked each to a reporter with a minimal promoter and integrated each into the Hprt locus of mouse ES cells. Using quantitative reverse transcription (RT)-PCR as a validation assay, we observed robust enhancer activity for all six SIF-seq-predicted enhancers ( Fig. 3) . This is in contrast to the sequences predicted to have no enhancer activity by SIF-seq, including the four sites with p300 and/or H3K27ac interaction, all of which had negligible reporter expression. Collectively, the enhancers predicted by SIF-seq drove significantly higher reporter expression than those that were predicted by SIF-seq to have no enhancer activity ( Fig. 3 , P = 5 × 10 −5 , one-tailed t-test). The high validation rate in these complementary assays demonstrates the accuracy of de novo predictions of enhancers by SIF-seq.
identification of poorly conserved es cell enhancers
To explore the potential utility of this approach for mapping and characterizing human noncoding regulatory sequences, we next tested SIF-seq on mouse ES cells with integrated human sequences.
We built a DNA fragment library from a randomly sheared BAC (RP11-103J24) containing ~160 kb of human sequence encompassing the NANOG gene. Outside of the immediate NANOG locus, the University of California Santa Cruz (UCSC) Genome Browser net alignment track 24 for this region showed minimal sequence conservation between human and mouse ( Fig. 2b) . This lack of homology largely prevents the combined use of mousederived data and human-mouse sequence orthology to identify distally active enhancers at the human locus. Using SIF-seq, we randomly interrogated enhancer activity in ~1 kb fragments across the BAC region and identified two ES cell enhancers, one just downstream of NANOG and one between NANOGNB and CLEC4C ( Fig. 2b and Supplementary Fig. 3b ). To confirm that these human sequences are bona fide ES cell enhancers, we validated their activity by individually testing them in mouse ES cells. Both putative enhancers robustly activated reporter gene expression ( Supplementary Fig. 5 ). Furthermore, both sites showed Encyclopedia of DNA Elements (ENCODE) chromatin profiles consistent with strong human ES cell enhancer activity ( Supplementary Fig. 3b ) 25 . We identified neither locus as an npg enhancer at the mouse Nanog locus, as they both had little to no sequence conservation to mouse.
siF-seq enhancer identification in additional cell types
Previously available higher-throughput mammalian enhancer assays rely largely on transient transfection of cells or tissues [16] [17] [18] , which can increase throughput and sampling depth but severely limits the use of these assays to easily transfectable cell types and precludes the discovery of enhancers active in many biologically or disease-relevant cell types. Therefore, we next explored whether SIF-seq can be used to identify enhancers in additional, disease-relevant cell types by using in vitro differentiation of ES cells. We constructed libraries with a randomly sheared BAC (RP11-929J10) containing human genes important for heart function, MYH6 and MYH7, and integrated these into the Hprt locus in mouse ES cells as before. We carried out SIF-seq at the initial ES cell stage and upon differentiation of those cells to cardiomyocytes. For the MYH6 and MYH7 region, we randomly interrogated enhancer activity in ~1 kb DNA fragments across the BAC at the pluripotent ES cell stage and identified one sequence that was enriched in the reporter expressing cells: the promoter of the ubiquitously expressed PABPN1 gene (Fig. 4) . In ES cells differentiated into cardiomyocytes, four sites were enriched in the reporter-expressing cells: the PABPN1 promoter, the MYH6 promoter and two putative enhancers upstream of MYH7 that are active in cardiomyocytes. One of these enhancers (hs1670) had been identified previously in a larger-scale enhancer screen 13 and drives strong, reproducible reporter gene expression throughout the heart in transgenic mouse reporter assays at embryonic day 11.5 (E11.5) 26 (Fig. 4) . We also validated the second putative enhancer, hs2330, using a transgenic mouse assay and found that 11 of 14 embryos had reproducible enhancer activity throughout the heart at E11.5 ( Fig. 4) .
Finally, to test the feasibility of using SIF-seq in neuronal cell types and to determine whether SIF-seq can be used to validate large numbers of putative enhancers identified by other complementary methods, we pooled together 192 noncoding sequences from the human genome that had been identified via comparative genomics approaches as having extreme evolutionary sequence conservation ('ultraconservation') in vertebrates 27, 28 . These sites had been previously tested for enhancer activity in transgenic E11.5 mice 27, 28 . We integrated the pooled sequences into the Hprt locus of ES cells as before and then differentiated the cells to Nestin + neural progenitors. Of the 192 sites we attempted to integrate in mouse ES cells, 153 (80%) sites integrated into Expression of reporter genes driven by the indicated enhancers (SIF-seq enhancer-positive and enhancer-negative predictions are shown in red and light gray, respectively), relative to positive and negative controls (dark gray). Reporter gene expression was normalized to expression of actin and was then normalized to the positive control, which was set at 1. Bars indicate the mean reporter gene expression for each sample, and individual points show the results for technical quantitative RT-PCR replicates (n = 9 reactions for the control samples, n = 3 reactions for remaining samples). Sample names include the library from which the enhancer was identified (Nanog or Sall); whether the locus was identified as an enhancer by SIF-seq (SIFS), ChIP-seq but not SIF-seq (p300) or neither method (Neg); and a unique numerical identifier. Inset, summary of RT-PCR results for the indicated groups of samples (P = 5 × 10 −5 by one-tailed t-test; boxplots show first and third quartiles (boxes) and median of each data class, whiskers indicate data ranges 1.5 times the interquartile range from the nearest quartile, and outliers are represented by dots. npg genomes of the neural progenitor library; of these, eight were significantly over-represented in the reporter-expressing cells (P < 10 −6 using a conservative Poisson estimation; Supplementary  Fig. 6a,b) . Six of the eight (75%) over-represented sequences had reproducible enhancer activity in the central nervous system in mice at E11.5 (Supplementary Fig. 6c ) 27, 28 . Despite the in vitro neural progenitor differentiation likely representing an earlier stage in development than E11.5, this is a substantial enrichment of central nervous system enhancers (75% compared to a background rate of 29% enhancers with central nervous system activity across the 153 elements contained in the test library 27, 28 , P < 0.05, one-tailed Fisher's exact test; Supplementary Fig. 6d) .
discussion
With SIF-seq and ES cell differentiation protocols, we accurately mapped tissue-specific enhancers active in ES cells, cardiomyocytes and neural progenitor cells. This demonstrated that SIF-seq can be used to identify enhancers in a range of biologically or disease-relevant cell types, limited only by currently available stem cell differentiation methods. We found that the ES cell enhancers present at the NANOG locus differed substantially between mouse and human. These experiments demonstrated that human ES cell enhancers that are not present in the mouse genome can still be identified using reporter assays in mouse ES cells. Although we did not explicitly test the activity of species-specific enhancers, such as those derived from certain classes of repetitive elements 29 , these results strongly suggest that SIF-seq can be used to identify enhancers from other mammalian genomes where desired cell types are difficult or impossible to obtain. By performing unbiased enhancer discovery across several genomic loci, we compared SIF-seq and ChIP-seq-based methods for enhancer discovery. In mouse ES cells, for which we had access to the most comparable ChIP-seq data 3 , all SIF-seqidentified enhancers had robust p300 and H3K27ac interactions. However, many sites that according to ChIP-seq data had p300 and/or H3K27ac interactions were not identified as enhancers by SIF-seq. In independent validation assays, all six tested SIFseq-identified mouse ES cell enhancers had activity, in contrast to all four of the tested SIF-seq enhancer-negative sites with p300 and/or H3K27ac interactions. These validation results indicate that SIF-seq may predict enhancers more accurately than certain chromatin-based methods.
The need for higher-throughput assays to directly interrogate enhancer activity has led to the recent development of multiplex methods to functionally assess genetic regulatory elements [16] [17] [18] [30] [31] [32] [33] . However, with the exception of one method to test enhancers in Drosophila embryos 32 , all of these methods rely on transient delivery of enhancer-reporter plasmids, limiting the use of these methods to a small number of easily transfected cell types. Furthermore, many enhancers have been shown to have negligible activity when tested in transient assays but robust activity when integrated into the genome [34] [35] [36] . This suggests that transient delivery of enhancer-reporter constructs may not recapitulate the native chromatin environment found in chromosomes, which may be necessary for proper gene regulation. SIF-seq improves substantially on these previous methods by assessing mammalian enhancer activity in a genomic context and in a potentially much wider variety of cell types.
Currently, the number of putative enhancers assessed in a single SIF-seq experiment is limited by the efficiency of site-specific genome integration of the reporter construct in mouse ES cells. For the experiments described, genome integration into the Hprt locus occurred in approximately one in 10 5 mouse ES cells, corresponding to ~1,500 individual integration events per library. New genome editing technologies, particularly those using clustered regularly interspaced short palindromic repeats (CRISPR) and Cas9 37-39 , may improve this integration efficiency and thereby increase the throughput of this approach. The use of CRISPR-Cas9 or other editing technologies could also potentially allow for the use of SIF-seq in already differentiated cell lines that are not readily amenable to targeted genome integration.
Because enhancers have important roles in development and because of the mounting evidence for their contributions to human disease, the identification of enhancer elements in different cell types and under different biological conditions is currently of high priority in biomedical research. The use of SIF-seq will help to surmount the considerable limitations currently curbing the ability to functionally identify or validate large numbers of putative enhancers directly in many disease-relevant cell types. For example, the expanded use of this method has the potential to decrease the need for transgenic mice to test enhancers active in specific cell types. In addition to enhancer identification and validation, this method should also be easily adapted to study the effects of allelic variants on enhancer activity, a technique that will become increasingly important as wholegenome sequencing is progressively adopted in human disease studies. The use and development of SIF-seq will allow for the more comprehensive study of the roles of enhancers in human health and disease.
methods
Methods and any associated references are available in the online version of the paper.
Accession codes. Sequence Read Archive: SRP034877.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper. online methods Targeting vectors. Descriptions of the Hprt targeting vectors used are given in Supplementary Note 1, and the vectors have been made publically available through Addgene (plasmids #51291 and #51292).
Constructing plasmid libraries. BACs were ordered from the BACPAC Resource Center at Children's Hospital Oakland Research Institute. BAC DNA was sheared with a Bioruptor XL (Diagenode) or a Sonifier II 450 (Branson), and ~1-1.6 kb long DNA fragments were size-selected using agarose gel electrophoresis. Although we limited our libraries to this size range, DNA fragments can be sheared to a variety of smaller or larger size ranges to identify larger or smaller enhancers, depending on the specific application. Size-selected DNA was purified using the QIAquick Gel Extraction Kit (Qiagen). Purified DNA was end-repaired using the End-It DNA End-Repair Kit (Epicentre) and purified using the QIAquick PCR Purification kit (Qiagen) according to manufacturer's instructions. A-tailing was carried out in a 50 µl reaction containing 1× NEBuffer 2 (New England BioLabs), 15 U Klenow fragment (3′ to 5′ exo − ) (New England BioLabs) and 0.2 mM dATP (Roche), and incubated at 37 °C for 30 min. The DNA was again purified using the QIAquick PCR Purification kit before adaptor ligation.
Cloning adaptors were made using the following HPLCpurified oligos: Adaptor-attB1 and Adaptor-attB2 (Supplementary Table 2 ). Adaptor oligos were mixed in equimolar amounts and prepared by denaturing at 95 °C on a heat block and annealing by allowing the heat block to slowly return to room temperature.
Cloning adaptors were ligated to the library of DNA fragments using the NEBNext Quick Ligation Module (New England BioLabs) according to manufacturer's instructions with a 2 µM final concentration of cloning adaptors. The DNA library was purified from the unligated adaptors using either 35 µl of AMPure XP beads (Beckman Coulter) per 50 µl ligation reaction according to manufacturer's instructions ('hNANOG' and 'mNanog' libraries) or agarose gel electrophoresis size selection (all remaining libraries). The DNA concentration of the fragment library was measured using the Qubit dsDNA HS Assay and a Qubit Fluorometer (Life Technologies). Correctly adapted DNA fragments were enriched by PCR amplification in a 50 µl PfuUltra II Fusion HS DNA polymerase (Agilent) reaction using 5-10 ng of library DNA and the following primers: attB1F and attB2R (Supplementary Table 2 ). Cycling conditions were as follows: initial 95 °C denaturation for 2 min, 20 cycles of amplification (denaturation at 95 °C for 20 s, primer annealing at 65 °C for 20 s and extension at 72 °C for 15 s) and final extension at 72 °C for 3 min.
After amplification, 1-1.6 kb library fragments were again size-selected on a 1% agarose gel and QIAquick Gel Extraction kit purified as described above except that the library was eluted in a final volume of 25 µl. The DNA libraries were cloned into either pSKB1-GW-hsp68-Venus (mSall1 and ultraconserved libraries) or pSKB1-Venus-H19 (all remaining libraries) using a single-tube, two-step Gateway cloning reaction (Life Technologies) as follows: up to 100 ng of the PCR amplicon library was incubated with 200 ng pDONR221 plasmid and 3 µl BP Clonase II Enzyme Mix in a 15 µl total reaction volume. After a room temperature incubation for ~20 h, 10 µl of this reaction was mixed with 2 µl of 150 ng/µl pSKB1-GW-hsp68-Venus or pSKB1-Venus-H19 and 3 µl LR Clonase II enzyme mix and incubated at room temperature for ~20 h.
Plasmid libraries were transformed by electroporating 1 µl of each LR Clonase II reaction into 50 µl of One Shot TOP10 Electrocomp Escherichia coli (Life Technologies). After a 30-min recovery incubation in rich super optimal broth with catabolite repression (SOC) medium, the transformed cells were transferred to 500 ml LB medium containing 200 µg/ml ampicillin and grown at 37 °C for ~12.5 h. Plasmid DNA was isolated using the Plasmid Maxi kit (Qiagen) with manufacturer-recommended protocol modifications for large, low-copy plasmids. Plasmid DNA was linearized with PmeI (NEB) and then purified by phenolchloroform extraction, washed with 70% ethanol, and resuspended in buffer containing 10 mM Tris-HCl and 0.1 mM EDTA with a pH of 7.5.
Making embryonic stem cell libraries.
All experiments used the E14Tg2a.4 (ref. 40 ) male mouse ES cell line, which has a 36-kb X chromosome deletion that removes the first two exons of the Hprt gene. Cells were grown under feeder-free conditions on gelatin-coated plates and fed standard ES cell medium: Knockout DMEM (Life Technologies) containing 15% FBS (HyClone), 2 mM l-glutamine (Life Technologies), 0.1 mM nonessential amino acids (Life Technologies), 0.05 mM 2-mercaptoethanol (Sigma), 1,000 U/ml ESGRO LIF (Millipore) and penicillin-streptomycin. Cells were fed daily. Approximately 20 µg of linearized plasmid DNA was transfected into 1-1.5 × 10 7 ES cells in 0.8 ml HEPESbuffered saline (Sigma-Aldrich) using a Gene Pulser Xcell (Bio-Rad) set to 250 V and 500 µF. Ten such transfections were performed for each library. Correctly targeted cells were selected by the addition of hypoxanthine-aminopterin-thymidine (HAT) supplement (Life Technologies) to the ES cell medium for 3-10 d, beginning 24 h after transfection. After HAT selection, cells were fed ES cell medium containing 1× HT supplement (Life Technologies) for 2 d. Cells from the same library were pooled together and expanded on fresh plates before sorting.
Sorting. Before sorting, cells were washed with PBS and collected using trypsin. Cells were pelleted by centrifugation, the trypsin was removed and the cells were washed with PBS. Cells were resuspended in 1% w/v saline by repeated pipetting and passed through a 0.4-µm strainer to ensure single-cell suspension. Cells were sorted on an Influx cell sorter (BD Biosciences) using Spigot Version 6.1.10 software (BD Biosciences). Flow cytometry metrics were analyzed using FlowJo Version 7.6.3 (TreeStar).
In vitro differentiation. Mouse ES cell differentiation to cardiac
troponin T-expressing cardiomyocytes was carried out as previously described 41, 42 . Differentiation to neural progenitors was carried out as previously described 43, 44 without the use of cyclopamine, and cells were collected on day 14. Differentiated cells were fixed in 4% paraformaldehyde for 15 min and washed with PBS before sorting.
PCR amplification of inserts and sequencing. DNA was isolated from both Venus-expressing and unsorted control populations of cells using the QIAamp DNA Mini kit (Qiagen). The enhancer position sites were amplified from the genomic DNA npg
